Washington U gets second look at Pfizer molecules

In a fresh sign of Pfizer's interest in tapping some expert development help outside the company, the pharma giant has committed $22.5 million to a five-year pact with the medical school at Washington University in St. Louis that will lay out 500 of its molecules for a close second look. In the deal, researchers at Washington University will get a chance to take a careful look at possible new indications for approved molecules or therapies now in development. It will also hand over molecules that have failed in clinical trials to see if the university researchers can find a promising application that Pfizer may have overlooked. Report

Suggested Articles

Data from a 10,000-patient trial showed that people with osteoarthritis taking Novartis' Ilaris had 40% to 47% lower rates of joint replacements.

Immunic's lead asset beat placebo at reducing damage to myelin, which protects nerve fibers, in patients with relapsing multiple sclerosis.

The appointment sees Kobayashi switch from developing Dermira’s anti-IL-13 drug to advancing Aslan’s would-be rival.